Heart failure & cardiomyopathies
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Authors' conclusion
Select demographics, clinical factors, and global regions contribute to a higher incidence of HF events among PWH. In PWH, the observed overall number of HF events aligned with the estimated Predicting Risk of Cardiovascular Disease Events HF risk rates.
Study context
- Population
- People with HIV with low-to-moderate estimated atherosclerotic CVD riskmedian 50 years
- Participants
- 7,769 people
- Primary endpoint
- HF incidence (events/1000 person-years): adjudicated HF hospitalization and adverse events by standardized HF query
- Follow-up
- Median 5.6 years (IQR, 4.3-5.9)
Methodological details5 global regions
- 5 global regions
Primary result
As reported in the abstract
HF incidence · median follow-up 5.6 years
Overall heart failure (HF) incidence
1.65/1000 person-years
95% CI 1.30–2.09
Further findings
PREVENT HF risk score vs observed HF events
- Median (Q1-Q3) PREVENT HF score, 1.01-2.62
- 1.66%
- Expected HF events by PREVENT HF
- 73
- Observed HF events (consistent with expected)
- 67
Original publication
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Circ Heart Fail. Published 29 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →